Daratumumab resistance is frequent in advanced stage multiple myeloma patients irrespectively of CD38 expression, and is related to dismal prognosis

ConclusionsResponses to daratumumab and combinations in patients with advanced MM, particularly with extramedullary disease, are low and short lived, stressing the administration of this agent should be early in the course of the disease.This article is protected by copyright. All rights reserved.

Source: European Journal of Haematology - February 17, 2018 Category: Hematology Authors: M Pick, V Vainstein, N Goldschmidt, D Lavie, D Libster, A Gural, S Grisariu, B Avni, D Ben Yehuda, M.E Gatt Tags: Original Article Source Type: research